Author: K-STOCK Editor
[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Application for CT-P13 SC (Remsima Subcutaneous) in Pediatric Crohn’s Disease in Korea / 2025-02-24
[Disclosure] Hanwha Systems (272210) – (Correction) Change in Revenue or Operating Profit/Loss by 30% or More / 2025-02-21